louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00557765: Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area
Official title: Production of Gamma-Interferon by Circulating Lymphocytes Exposed to Antigens Specific of Mycobacterium Tuberculosis: Contribution to the Identification of Latent Tuberculosis Infection in Contact Tracing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Latent Tuberculosis Infection
Keywords: Tuberculosis
Latent tuberculosis infection
Interferon gamma release assay
Contact tracing
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
Collaborators: name: Ligue Pulmonaire Genevoise
First posted: 2007-11-14
Enrollment: 295
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All subjects screened after exposure to a case of active and contagious tuberculosis in the Geneva area

Brief summary: After exposure to an active case of tuberculosis (TB), close contacts may be infected. They are then considered as having latent tuberculosis infection (LTBI). Detecting LTBI is the main goal of contact tracing procedures after exposure to TB. Until recently, the only test available for detecting LTBI was the tuberculin skin test (TST). More recent tests are now available (Interferon-gamma release assays: IGRA), which are more specific and sensitive than the TST. This study compares the TST and an IGRA in the routine activity of contact tracing in our area.

Detailed description: Setting: A TB clinic in Geneva, Switzerland, a low incidence area for TB with a high immigrant population.

Aim of study: to compare results of an IGRA test (T-SPOT.TB, Oxford Immunotec, UK) and the TST, and their correlation with exposure scores in subjects exposed to cases of contagious TB.

Methods: Prospective study of all contacts screened in our area, and accepting to be included. Simultaneous recording of age, gender, origin, history of recent travels or exposure, BCG vaccination status, infectiousness of index case, 5 different exposure scores, TST, and result of the T-SPOT.TB blood test. Univariate and multivariate analysis.

Eligibility criteria: Inclusion Criteria:

* Exposure to a case of contagious TB
* Willingness to participate in study

Exclusion Criteria:

* Known HIV infection
* Known previous TB or treatment for LTBI

Primary outcomes:
measure: Correlation between results of TST and IGRA tests and exposure scores
timeFrame: 2 months after exposure
Secondary outcomes:
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Centre antituberculeux; Geneva University Hospital
Study officials:
affiliation: Centre antituberculeux
name: Jean-Paul Janssens, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06168565: Hemodynamic Effects of Intermittent Pneumatic Compression for Sports
Official title: Hemodynamic Effects of Intermittent Pneumatic Compression for Sports: A Double-blinded Randomized Crossover Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sports Physical Therapy
Keywords: sports
recovery
intermittent pneumatic compression
Lead sponsor: University of Maia
Sponsor class: OTHER
First posted: 2023-12-13
Enrollment: 23
Sex: MALE
Minimum age (years): 18
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this randomized crossover trial is to assess the hemodynamic effects caused by the use of 2 distinct intermittent pneumatic compression protocols on athletes.

The main questions it aims to answer are:

* Does intermittent pneumatic compression enhance athletes blood flow?
* If yes, what pressure is better to cause this enhancement?


Eligibility criteria: Inclusion Criteria:

* male gender
* healthy
* competing in soccer of track and field for at least two years
* not have performed any physical activity on the data collection day

Exclusion Criteria:

* more than one risk factor for thromboembolism (e.g., use of tobacco, varicose veins)
* injured athletes

Primary outcomes:
measure: Arterial Diameter
timeFrame: 2 minutes before the IPC protocol, during (8th minute mark), and 2 minutes after the conclusion of the 15 minute protocol.
measure: End-diastolic peak velocity
timeFrame: 2 minutes before the IPC protocol, during (8th minute mark - at different phases of the IPC cycle), and 2 minutes after the conclusion of the 15 minute protocol.
measure: Systolic peak velocity
timeFrame: 2 minutes before the IPC protocol, during (8th minute mark - at different phases of the IPC cycle), and 2 minutes after the conclusion of the 15 minute protocol.
Secondary outcomes:
measure: Heart rate
timeFrame: 2 minutes before the IPC protocol, during (8th minute mark - at different phases of the IPC cycle), and 2 minutes after the conclusion of the 15 minute protocol.
Other outcomes:
Locations:
city: Maia
country: Portugal
facility: University of Maia
Study officials:
References:
Clinical trial NCT04618965: Intrathecal Versus Intravenous Dexmeditomedine in Transurethral Resection of the Prostate
Official title: The Effect of Intrathecal Versus Intravenous Dexmeditomedine on Postoperative Analgesia in Transurethral Resection of the Prostate
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Dexmedetomidine
Transurethral Resection of Prostate
Intravenous
Intrathecal
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2020-11-06
Enrollment: 75
Sex: MALE
Minimum age (years): 59
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to evaluate The analgesic effect of intrathecal versus intravenous dexmeditomedine in transurethral resection of the prostate

Detailed description: This study will carried out in Tanta University hospital on75 male patients Patients will randomly classified into 3 groups Group I: will receive intrathecal hyperbaric bupivacaine 10mg in 2.5 ml and .5 ml saline with 3ml total volume Group II: will receive dexmeditomedine 5Mic diluted in.5 ml saline and hyperbaric bupivacaine 10mg in 2.5ml with 3ml total volume Group IIl: Will receive intravenous dexmeditomedine started at loading dose of 1 mic/kg diluted in 50 ml saline and administered within 10 min as loading dose , followed by maintenance at a dose of .4mic/kg/h diluted in200 ml saline till the end of surgery and hyperbaric bupivacaine 10 mg in 2.5 ml total volume

Eligibility criteria: Inclusion Criteria:

* male gender
* 50:70years old
* ASA:I,II

Exclusion Criteria:

* contraindications of spinal anesthesia
* Patient refusal
* Patient taking alpha agonist or antagonist
* Uncontrolled cardiac diseases
* Allergy to local anesthetic drugs

Primary outcomes:
measure: The time to first rescue analgesic
timeFrame: 24 hours postoperative
Secondary outcomes:
measure: Postoperative pain score Total dose of analgesic consumption I the first postoperative day Intraoperative and postoperative complications
timeFrame: 24 hours postoperative
measure: Total analgesic consumption
timeFrame: 24 hours postoperative
measure: Intraoperative and postoperative complications
timeFrame: Intraoperative and 24 hours postoperative
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04425265: Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
Official title: A Randomized Controlled Trial of Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Surgery
Recurrent Nasopharyngeal Carcinoma
Keywords: recurrent nasopharyngeal carcinoma
Plasma Radiofrequency Ablation
Electrocautery Block Resection
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2020-06-11
Enrollment: 248
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims at exploring whether plasma radiofrequency ablation at low temperature is associated with better survival outcome in localized recurrent nasopharyngeal carcinoma by conducting a randomized controlled trial of plasma radiofrequency ablation at low temperature versus electrocautery block resection at high frequency for localized recurrent nasopharyngeal carcinoma. If the hypothesis is confirmed, it is expected to provide a convenient choice for the surgical treatment of localized recurrent nasopharyngeal carcinoma.


Eligibility criteria: Inclusion Criteria:

1. At least 6 months disease free interval (defined as duration between the initial course of radiotherapy and recurrence)
2. Histopathologically diagnosed with undifferentiated or differentiated, nonkeratinizing nasopharyngeal carcinoma.
3. Resectable recurrent nasopharyngeal carcinoma:

   A) recurrent T1N0M0 according to the American Joint Committee on Cancer (AJCC) 8th staging B) recurrent T2N0M0(the tumor was confined to the surface of the parapharyngeal space and was more than 0.5cm away from the internal carotid artery) according to the American Joint Committee on Cancer (AJCC) 8th staging
4. Age: 18-70 years old.
5. Subjects must sign an informed consent form.

Exclusion Criteria:

1. Karnofsky score (KPS)≤70.
2. Has known Subjects with other malignant tumors.
3. Has seriously mental disease.
4. Uncontrolled clinically significant heart disease and Pulmonary dysfunction.
5. Pregnancy or breast feeding.

Primary outcomes:
measure: Progression-free survival
timeFrame: 2 years
Secondary outcomes:
measure: Overall survival
timeFrame: 2 years
measure: Loco-regional relapse-free survival
timeFrame: 2 years
measure: Distant metastasis-free survival
timeFrame: 2 years
measure: Incidence of surgery related complications
timeFrame: 1 year
measure: Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0)
timeFrame: 1 year
measure: Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35)
timeFrame: 1 year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangdong
Study officials:
References:
Clinical trial NCT04641065: Traditional Turkish Military Music and Endoscopic Retrograde Cholangiopancreatography
Official title: Effects of Traditional Turkish Military Music on Pain, Anxiety and Vital Signs in Patients With Endoscopic Retrograde Cholangiopancreatography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endoscopic Retrograde Cholangio-Pancreatography
Anxiety
Pain
Lead sponsor: Afyonkarahisar Health Sciences University
Sponsor class: OTHER
First posted: 2020-11-23
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to investigate the effect of Traditional Turkish Military music on patients who will have Endoscopic Retrograde Cholangio-Pancreatography Procedure on vital signs, anxiety, and pain. This will be a randomized controlled experimental study.

The study will be conducted with two groups: the intervention group (n=36) and the control group (n=36). The control group will receive standard care while the intervention group, in addition to standard care, will be listened to Traditional Turkish Military music, which consists of music selected by an expert on the type of music, by the researchers for 15 minutes before the procedure.


Eligibility criteria: Inclusion Criteria:

* patients aged 18 or above,
* with a scheduled ERCP procedure
* with the ASA grade level of I-II clinically
* without a hearing/speech impairment
* willing to participate in the research
* without a mental problem or diagnosis of psychiatric disorder
* without any a diagnosis of depression

Exclusion Criteria:

* patients below 18 years of age,
* Patients with an emergency ERCP procedure
* with a hearing/speech impairment
* not willing to participate in the research
* with a mental problem or diagnosis of psychiatric disorder
* with a diagnosis of depression

Primary outcomes:
measure: Visual Analog Scale for Anxiety (VAS-A)
timeFrame: 1 Hour
measure: Visual Analog Scale for Pain (VAS)
timeFrame: 2 Hours
Secondary outcomes:
measure: Vital Signs
timeFrame: 4 Hours
measure: Vital Signs
timeFrame: 4 hours
measure: Vital Signs
timeFrame: 4 hours
Other outcomes:
Locations:
city: Afyonkarahisar
country: Turkey
facility: Afyonkarahisar Health Sciences University Hospital,
Study officials:
affiliation: Afyonkarahisar Health Sciences University
name: Yeliz CIGERCI, Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05365165: Researching the Affect of Sevoflurane in Cardiac Surgery on Delirium
Official title: Researching the Affect of Sevoflurane Application for Maintenance of Anesthesia During Aortic Cross-clamping in Cardiac Surgery on Delirium
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Postoperative Delirium
Lead sponsor: Derince Training and Research Hospital
Sponsor class: OTHER
First posted: 2022-05-09
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who will have elective open heart surgery, patients over the age of 18, and patients with a score of 25 and above in the mini mental state test performed in the preoperative period will be included in the study.

Brief summary: Many risk factors have been identified for delirium after open heart surgery . One of the main risk factors; duration of stay on mechanical ventilator . Our hypothesis; The use of sevoflurane during aortic cross-clamping reduces the need for long-acting intravenous anesthetic agents. Therefore, patients will be weaned from the mechanical ventilator in a shorter time. Patients with shorter stays on mechanical ventilation develop less postoperative delirium.

Detailed description: Standard anesthesia management will be applied in the induction and maintenance of anesthesia. In the induction of anesthesia 1mg/kg lidocaine , 1.5-2mg/kg propofol , 1 mcg /kg fentanyl citrate, 0.6 mg/kg rocuronium bromide will be administered. Sevoflurane for maintenance of anesthesia and propofol and fentanyl if needed bolus will be applied. BIS monitoring will be performed to control the depth of anesthesia. Patients' peroperative hemodynamic levels, arterial blood gas levels, operation time, pump time, aortic cross clamp time, postoperative complications , the amount of blood and fluid used, the amount of iv anesthetic used, the extubation time, the length of stay in the intensive care unit, the length of stay in the hospital will be followed and recorded. Postoperative delirium follow-ups of the patients will be recorded once a day by the same investigator using the Nursing Delirium Screening Scale and Delirium Rating Scale Revised-98 until they are discharged from the hospital .

Eligibility criteria: Inclusion Criteria:

Patients with a score of 25 and above in the mini-mental state test performed in the preoperative period

Exclusion Criteria:

Those who are scheduled for emergency surgery

Those with known dementia and/or neurological disease

Primary outcomes:
measure: rate of delirium after open heart surgery
timeFrame: up to 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Ayşegül Çiğdem Çağlayan
Study officials:
References:
Clinical trial NCT02826265: Evaluation of Novel Lung Function Parameters and Quantitative Computed Tomography (qCT) in Patients With Pulmonary Disease
Official title: Evaluation of Novel Lung Function Parameters and Quantitative Computed Tomography (qCT) in Patients With Pulmonary Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Obstructive Pulmonary Disease
Bronchial Asthma
Interstitial Lung Disease
Lead sponsor: Universitätsmedizin Mannheim
Sponsor class: OTHER
First posted: 2016-07-07
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with indication for routine lung function testing and computed tomography

Brief summary: Current diagnostic tools used in pulmonary disease often do not meet the challenges set by the respective pathophysiology. The investigators therefore aimed to evaluate novel or not widely used diagnostic approaches for the detection and therapeutic monitoring of patients with various pulmonary diseases.


Eligibility criteria: Inclusion Criteria:

* known or suspected pulmonary lung disease
* indication for computed tomography

Exclusion Criteria:

* pregnancy
* inability to participate

Primary outcomes:
measure: correlation of lung clearance index (LCI) as determined by multiple breath washout with emphysema quantification as determined by qCT
timeFrame: 2 weeks
measure: correlation of airway resistance and reactance (R5, X5, R-D5-20) as determined by impulse oscillometry with emphysema quantification as determined by qCT
timeFrame: 2 weeks
measure: correlation of residual volume and airway resistance as determined by body plethysmography with and emphysema quantification as determined by qCT
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Mannheim
country: Germany
facility: Universitätsmedizin Mannheim
Study officials:
References:
Clinical trial NCT00169065: Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
Official title: Clozapine vs. Olanzapine: An Effectiveness Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Schizophrenia
Keywords: Clozapine
olanzapine
Lead sponsor: Harvard Medical School (HMS and HSDM)
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
name: Dartmouth-Hitchcock Medical Center
name: Commonwealth Research Center, Massachusetts
name: Eli Lilly and Company
First posted: 2005-09-15
Enrollment: 38
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.

Detailed description: This is a two-year open-label, randomized trial of the comparative effectiveness of clozapine versus olanzapine in patients with treatment refractory schizophrenia. The objective is to determine whether in a naturalistic setting olanzapine is a logical treatment choice (before using the more toxic clozapine) for some treatment refractory patients.

Eligibility criteria: Inclusion Criteria:

* Age 20-60 years;
* Diagnosis of treatment refractory schizophrenia or schizoaffective disorder;
* BPRS score \> 21 (0-6) scale;
* Either two 6-8 week trials of typical neuroleptics given at a dosage of 600 mg/day of CPZ or its equivalent or one 6-8 week trial of an atypical antipsychotic at a reasonable dose (i.e. risperidone 4-6 mg/day);
* The patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent;
* Clinically appropriate for clozapine or olanzapine

Exclusion Criteria:

* Current substance abuse;
* Suicide or homicide risk;
* Pregnancy or lactation;
* History of seizures or blood dyscrasias

Primary outcomes:
measure: Changes in quality of life.
Secondary outcomes:
measure: Symptom measures, neurological side effects, neuropsychological performance, patient satisfaction and burden on the family.
Other outcomes:
Locations:
city: Jamaica Plain
country: United States
facility: Commonwealth Research Center
state: Massachusetts
Study officials:
affiliation: Harvard Medical School (HMS and HSDM)
name: Alan I Green, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05232565: Prospective Multicenter Study to Characterize the REAL-WORLD EVIDENCE Regarding Safety and Performance of the PTCA Catheters Family
Official title: Prospective Multicenter Study to Characterize the REAL-WORLD EVIDENCE Regarding Safety and Performance of the PTCA Catheters Family
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Stenosis
Lead sponsor: Arthesys
Sponsor class: INDUSTRY
First posted: 2022-02-10
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing PTCA procedure

Brief summary: The purpose of this Post market Study is to collect clinical data of the Arthesys PTCA catheters family during angioplasty intervention of coronary vessels or coronary bypass graft stenosis to support MDR submission.


Eligibility criteria: Inclusion Criteria:

* Patient with a Percutaneous intervention to a native coronary or coronary bypass graft indication
* Patient \>18 years
* Patient who understands the trial requirements and the treatment procedures and provides written informed consent

Exclusion Criteria:

- Patients will not be included if they are under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision.

Primary outcomes:
measure: Efficacy endpoint
timeFrame: Up to end of PTCA procedure
measure: Safety endpoint
timeFrame: Up to end of PTCA procedure
Secondary outcomes:
measure: Performance - pre-dilatation
timeFrame: Up to end of PTCA procedure
measure: Performance - post-dilatation
timeFrame: Up to end of PTCA procedure
Other outcomes:
Locations:
city: La Rochelle
country: France
facility: Hôpital Saint Louis
Study officials:
References: